An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Part of paid clinical trials in San Diego, California.
- Sponsor
- Splice Bio
- Study ID
- NCT06435000
- Status
- Recruiting
Conditions
- STGD1
- Stargardt
- Stargardt Disease
- Stargardt's Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 65 Years
- Healthy Volunteers
- Not accepted
Study Details
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
Key Dates
- Start date
- Mar 29, 2024
- Status verified
- Aug 2025
- Primary completion
- Dec 31, 2026
- Completion
- Feb 28, 2027
Study Design
- Enrollment
- 75 participants (estimated)
Primary Outcome Measure
Document disease progression based on change from baseline in lesion size as measured by DDAF on FAF imaging [ Time Frame: 96 weeks ]
Central Contacts
- SpliceBio+34 934 02 04 56
Locations (14)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Shiley Eye Institute | San Diego | California | 92093 | Site 108 (PRINCIPAL_INVESTIGATOR) |
| UCHealth Sue Anschutz-Rodgers Eye Center | Aurora | Colorado | 80045 | Site 109 (PRINCIPAL_INVESTIGATOR) |
| Vitreo Retinal Associates | Gainesville | Florida | 32607 | Site 114 (PRINCIPAL_INVESTIGATOR) |
| Bascom Palmer Eye Institute | Miami | Florida | 33136 | Site 104 (PRINCIPAL_INVESTIGATOR) |
| Emory University | Atlanta | Georgia | 30322 | Site 107 (PRINCIPAL_INVESTIGATOR) |
| Wilmer Eye Institute, Johns Hopkins University MD 21287 | Baltimore | Maryland | 21287 | Site 111 (PRINCIPAL_INVESTIGATOR) |
| Massachusetts Eye and Ear Infirmary | Boston | Massachusetts | 02114 | Center for Clinical Research Site 105 (PRINCIPAL_INVESTIGATOR) |
| Kellogg Clinical Research Center | Ann Arbor | Michigan | 48105 | Site 106 (PRINCIPAL_INVESTIGATOR) |
| Columbia University Medical Center | New York | New York | 10032 | Site 113 (PRINCIPAL_INVESTIGATOR) |
| CUIMC/Edward S. Harkness Eye Institute | New York | New York | 10032 | Site 112 (PRINCIPAL_INVESTIGATOR) |
| Duke Eye Center | Durham | North Carolina | 27710 | Site 110 (PRINCIPAL_INVESTIGATOR) |
| Oregon Health & Science University | Portland | Oregon | 97239 | Site 103 (PRINCIPAL_INVESTIGATOR) |
| Retina Foundation of the Southwest | Dallas | Texas | 75231 | Site 102 (PRINCIPAL_INVESTIGATOR) |
| University of Wisconsin, Madison | Madison | Wisconsin | 53715 | Site 101 (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Diego, CA
Related Studies
- Phase 2 Tolerability and Effects of ALK-001 on Stargardt DiseasePHASE2 · Enrolling By Invitation · Alkeus Pharmaceuticals, Inc. · Phoenix, Arizona
- Inherited Retinal Degenerative Disease RegistryRecruiting · Foundation Fighting Blindness · Columbia, Maryland
- Rod and Cone Mediated Function in Retinal DiseaseRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- Stem Cell Ophthalmology Treatment Study IIRecruiting · MD Stem Cells · Westport, Connecticut